SCHRODERS URGES ASTRAZENECA TO RESTART TALKS WITH PFIZER

     (The following press release from Schroders was received by e-mail. The 
sender verified the statement.) 
Schroders notes with disappointment the quick rejection by the AstraZeneca 
Board of the latest offer from Pfizer and the decision of the Pfizer Board to 
draw a premature  end to these negotiations by calling their latest proposal 
Final.  As long term shareholders, we are strong believers in AstraZeneca and 
the potential for its innovative growth pipeline, however, given the increase 
in the offer we would encourage the AstraZeneca  management to recommence their 
engagement with Pfizer, and subsequently their shareholders.
 
 
Press spacebar to pause and continue. Press esc to stop.